2025-09-02

Ceuticoz, a leading brand in medical aesthetics and cosmeceuticals, is capitalising on the growing demand for science-driven, dermatologist-recommended skincare solutions.

With a presence in over 10 countries, the company is now eyeing further expansion into key international markets, including the United States, the United Arab Emirates, and Saudi Arabia. In an exclusive conversation with Pharma Industrial India, Sukhbir Singh Chimni, Managing Director of Ceuticoz, shares insights into the evolving landscape of medical aesthetics, the brand’s growth journey, and the future of clinically backed skincare in India.

Q. How has the medical aesthetics and cosmeceuticals industry evolved in recent years?

The medical aesthetics and cosmeceuticals industry has undergone a remarkable evolution in recent years, driven by rapid technological progress, changing consumer expectations, and breakthroughs in scientific research.

Science-backed skincare has become the new gold standard. Today’s consumers are no longer swayed by generic “natural” or “luxury” labels—they seek clinically validated, ingredient-focused solutions that are dermatologist-recommended. Active ingredients like retinoids, niacinamide, peptides, ceramides, and growth factors—backed by research and proven efficacy—are gaining significant traction. This has led to increased trust in medical-grade and cosmeceutical brands that bridge the gap between dermatology and skincare.

Medical aesthetic clinics are also evolving, increasingly integrating advanced treatments such as laser therapy, microneedling, and chemical peels with cosmeceutical aftercare. Many skincare brands are now designing dedicated post-procedure lines that promote healing, reduce inflammation, and maintain treatment results.

At the same time, ingredient trends are becoming globalized. K-beauty, J-beauty, and Ayurvedic influences are shaping product development across markets. Indian-origin brands like Ceuticoz are rising as strong global contenders, offering science-driven, results-oriented products that match international standards.

Personalized skincare is also on the rise, powered by AI-based skin analysis apps, tele-dermatology services, and digital diagnostic tools. Consumers are increasingly demanding custom regimens tailored to their skin type, environmental conditions, lifestyle, and specific concerns—marking a shift from the traditional one-size-fits-all approach.

Lastly, the rise of the “skintellectual” consumer—fueled by social media—has created a more informed and discerning audience. These consumers research ingredients, scrutinise formulations, and prioritise transparency. In this landscape, dermatologists and skincare experts have emerged as trusted influencers, further driving credibility for science-led cosmeceutical brands.

Q. How is Ceuticoz differentiating itself from other cosmeceutical brands?

Ceuticoz is strategically differentiating itself from other cosmeceutical brands by combining clinical credibility, affordability, and Indian dermatological relevance—while gearing up for global competitiveness.

Every Ceuticoz product is clinically driven and dermatologically validated, designed to treat specific skin concerns like acne, pigmentation, sensitivity, and aging. We use evidence-based actives like Tranexamic Acid, Niacinamide, Peptides, Retinoids, and patented ingredients with proven results. There is a major emphasis on derma-grade efficacy, not just cosmetic appeal, i.e. bridging the gap between pharmaceuticals and skincare.

Ceuticoz operates at the intersection of clinical dermatology and modern skincare, creating solutions that doctors trust and patients love. We boast of strong in-clinic presence and medical engagement with dermatologists across India.

Key Differentiator - Endorsed by dermatologists as both a treatment support and cosmetic enhancement, we offer medical-grade skincare at accessible prices, making science-backed skin health solutions available to a wider population. This is highly relevant in India and other developing markets, where price often limits access to clinical-grade skincare.

Ceuticoz stands apart by offering dermatologist-backed, medical-grade skincare that is affordable, ethical, and globally relevant—while being deeply rooted in Indian dermatology and scientific integrity.

Q. What have been some of Ceuticoz’s most recent achievements or milestones and financial highlights from the past year?

 Ceuticoz achieved its highest-ever monthly sales in both November and December 2024, crossing the INR 4 crore mark and reflecting strong double-digit revenue growth compared to the previous year. Expanding its international footprint, Ceuticoz entered the Canadian market with over eight SKUs, opening up new revenue streams globally.

The brand also began operations in Kenya and South Africa, launching more than 20 SKUs tailored to these regions. Domestically, Ceuticoz further strengthened its presence in the ethical dermatology segment across Odisha and Bengaluru, reinforcing its commitment to dermatological excellence.

Additionally, the company expanded its product portfolio by launching seven new skin-brightening products under its sub-brand IVORINE, catering to growing consumer demand for effective and science-backed skincare solutions

Q. Are there any plans for new product launches or R and D initiatives?

Yes, we are working to launch the pediatrics range with seven products in September 2025. The formulation and packaging have been finalised for all the products and currently we have put them for clinical and consumer studies.

Q. How has the company performed in terms of year-on-year growth?

Over the past three years, the company has achieved a compound annual growth rate (CAGR) of 33 percent.

Q. What is Ceuticoz’s current total revenue, and what is the projected revenue for FY 2025–26?

 Ceuticoz's expected India revenue for FY 2025-26 is INR 50 crore. Our efforts to extend our product line, increase market presence, and penetrate new markets, both domestically and globally, have fuelled this growth. Our focus on innovation, dermatologist collaborations, and community engagement will help us meet this goal and secure long-term success.

Q. What are Ceuticoz’s expansion plans in India and international markets?

Ceuticoz is committed to strengthening its ethical market presence in India by becoming the preferred brand for clinical dermatology prescriptions. We are enhancing medical engagement, expanding into Tier 2 and 3 cities, and launching education-driven initiatives to build trust. Following the success of our Ivorine Brightening Range, we are diversifying into post-procedure skincare solutions.

Internationally, Ceuticoz is present in more than 10 countries, with a strong foothold in Canada and ongoing expansion in the Middle East and Southeast Asia. Our vision is to establish Ceuticoz as a leading global Indian cosmeceutical brand—trusted by dermatologists, loved by patients, and backed by science.

Q. Which new markets or regions are you targeting in the coming year?

In the coming year, Ceuticoz plans to expand in the United States, the United Arab Emirates, and Saudi Arabia. These regions have substantial growth potential, thanks to increased demand for science-backed, dermatologist-recommended skincare products. We are continuously seeking to form strategic collaborations with local distributors, skincare clinics, and dermatologists in order to increase our presence and build confidence in these regions. Our mission is to establish Ceuticoz as a top choice in the worldwide cosmeceutical industry, providing high-quality, clinically proven skincare solutions to satisfy the unique demands of consumers in these regions.

Q. What are the company’s business targets for the next five years?

Ceuticoz's India business aims for the next five years are to achieve sustainable growth and enhance our global presence. Our goal is to increase income from INR 25-30 Cr per year to INR 150-200 Cr by FY 2029-30, with a CAGR of 30-35 percent. Our strategy will be based on ethical markets, product diversity, and worldwide expansion.

By FY 2030, we expect to generate 35-40 percent of our sales from overseas markets, with a presence in over 25 countries. In addition, we intend to establish a network of over 30,000 prescribing dermatologists and cosmetologists to reinforce our market position and ensure our sustained success.